Drugs / ACR246
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06238401 | Oct 2024 → May 2026 overdue | neoplasm | Hangzhou Adcoris Biopharmacy Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACR246 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238401 ↗ |
| Route | Intravenous | “Administered by intravenous infusion on Day 1 every 3 weeks (Q3W).” NCT06238401 ↗ |